# A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation

> **NCT06946927** · PHASE1 · RECRUITING · sponsor: **Jemincare** · enrollment: 72 (estimated)

## Conditions studied

- NSCLC (Advanced Non-small Cell Lung Cancer)

## Interventions

- **DRUG:** JMKX001899
- **DRUG:** IN10018
- **DRUG:** Chemotherapy: Pemetrexed
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT06946927
- **Lead sponsor:** Jemincare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-06
- **Primary completion:** 2026-02
- **Final completion:** 2027-12
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06946927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06946927, "A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06946927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*